Merck & Co Inc (MRK)
48.58USD
1 Aug 2013
$0.41 (+0.85%)
$48.17
$48.44
$48.68
$48.04
13,518,385
17,733,294
$50.16
$40.02
About
Overall
| Beta: | 0.58 |
| Market Cap (Mil.): | $145,454.70 |
| Shares Outstanding (Mil.): | 3,019.61 |
| Dividend: | 0.43 |
| Yield (%): | 3.57 |
Financials
| MRK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 28.68 | 37.93 | 37.76 |
| EPS (TTM): | 1.68 | -- | -- |
| ROI: | -- | 19.48 | 18.76 |
| ROE: | -- | 20.17 | 19.59 |
Cost controls help Pfizer, Merck weather weak quarter
- Big Pharma is still relying on belt-tightening to prop up financial results.
WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter
July 30 - Big Pharma is still relying on belt-tightening to prop up financial results.
Merck revenues miss mark as diabetes, arthritis drugs lag
- Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.
UPDATE 2-Merck revenue hit by weak overseas, consumer sales
July 30 - Merck & Co Inc's quarterly revenue fell short of expectations on disappointing results for the company's consumer and animal health products and weak overseas sales of prescription drugs that were slammed by the stronger dollar.
Merck revenue misses mark as diabetes, arthritis drugs lag
July 30 - Merck & Co's quarterly revenue fell short of Wall Street expectations, on lower sales of its consumer health and animal health products and weak growth of its treatments for diabetes and arthritis.
FDA accepts review of long-delayed Merck blood clot drug
July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.
UPDATE 1-FDA accepts review of long-delayed Merck blood clot drug
July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.
FDA accepts review of long-delayed Merck blood clot drug
July 24 - Merck & Co on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.
Merck drug to reverse anesthesia delayed again at FDA
WASHINGTON - U.S. health regulators need more time to review Merck & Co's application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery, the company said on Tuesday.
UPDATE 3-Merck drug to reverse anesthesia delayed again at FDA
WASHINGTON, July 16 - U.S. health regulators need more time to review Merck & Co's application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery, the company said on Tuesday.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Abbott Laboratories (ABT.N) | $36.84 | +0.21 |
| Eli Lilly & Co. (LLY.N) | $53.50 | +0.39 |
| Bristol Myers Squibb Co. (BMY.N) | $43.99 | +0.75 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (MRK). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

